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Abstract: This study was undertaken to assess vitamin D status in nonmenopausal women 
with metabolic syndrome (MeS) and to evaluate its possible role in inflammation and other 
components of MeS. A case-control study was conducted during late fall and winter 2009–10. 
A total of 375 women with waist circumference (WC) $88 cm were examined to find 100 
who met MeS criteria according to the National Cholesterol Education Program (NCEP)/Adult 
Treatment Panel (ATP) III criteria (NCEP/ATP III). Of those without MeS, 100 age- and resi-
dence area-matched women were selected as a control group. Anthropometric and laboratory 
evaluations were performed. Waist-to-hip ratio (WHR), body mass index (BMI), homeostatic 
model of insulin resistance (HOMA-IR) and body fat mass (FM) were also evaluated. Women 
with MeS had significantly higher BMI, waist circumference (WC) and FM but lower serum 
osteocalcin than controls. There was no significant difference in serum 25 hydroxyvitamin D 
(25[OH]D), intact parathyroid hormone (iPTH) or vitamin D status between the two groups. 
Serum highly sensitive C-reactive protein (hsCRP) concentration was significantly higher in 
the MeS group, compared to the controls (3.4 ± 3.3 vs 2.0 ± 1.9 mg/L, P , 0.001). The dif-
ference remained significant even after controlling for BMI (P = 0.011), WC (P = 0.014) and 
FM (P = 0.005). When comparison was made only in those subjects with insulin resistance 
(HOMA-IR . 2.4), hsCRP was still higher in the MeS group (n = 79) than in the control group 
(n = 61) (P , 0.001). When data were categorized according to vitamin D status, in the MeS group 
significantly higher plasma glucose concentrations were observed in subjects with vitamin D 
deficiency compared to those with insufficiency or sufficiency (104.0 ± 11.7, 83.0 ± 11.3 and 
83.2 ± 9.9 mg/dL, respectively, P , 0.001). Interestingly, their WC or WHR did not show any 
significant difference. In stepwise regression analysis, 25(OH)D was the main predictor of both 
hsCRP and plasma glucose. Vitamin D status may, at least in part, be a determining factor of 
systemic inflammation and the related metabolic derangements of MeS.
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Introduction
Metabolic syndrome (MeS) is characterized by several abnormalities including impaired 
glucose tolerance, blood lipid derangements, and prothrombotic and pro-inflammatory 
states.1 A number of studies have suggested abdominal obesity as the major culprit in 
MeS.2 It is believed that visceral fat, by secreting some inflammatory adipokines, brings 
about both insulin resistance and an inflammatory state.3 Elevated blood inflammatory 
biomarkers such as C-reactive protein (CRP), interleukin (IL)-6, IL-18 and tumor necro-
sis factor (TNF)-α have been found in individuals with MeS.4 Body fat mass (FM) and 
waist circumference (WC) have been found to be predictors of circulating highly sensi-
tive C-reactive protein (hsCRP) in Iranian middle-aged women.5 Fat distribution seems Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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to have a crucial role in the development of further metabolic 
disturbances. It has been shown that, unlike abdominal adi-
posity, gluteofemoral fat can be protective against metabolic 
derangements.6
Extra fat deposition in the body, depending on its loca-
tion, can adversely affect vitamin D status. Adipose tissue 
has been shown to act as a “metabolic well” for vitamin D, 
hence reducing its bioavailability.7 New studies support an 
inverse association between vitamin D status and insulin 
resistance, MeS and type 2 diabetes (T2D).8,9 A possible 
role for vitamin D deficiency in the pathogenesis of MeS has 
been recently proposed.10,11 Circulating 25 hydroxyvitamin D 
(25[OH]D) has been inversely associated with abdominal 
  adiposity, hypertriglyceridemia, and hyperglycemia.12 
  Vitamin D status may indirectly affect MeS development. 
Low serum osteocalcin, a vitamin D-dependent Gla-protein,13 
has been recently reported in subjects with MeS.14,15
The immune-modulatory effect of vitamin D and its 
inverse link with inflammation16 draws more attention to its 
possible role in MeS. Obesity and MeS are usually accom-
panied by “low-grade systemic inflammation”17 and aug-
mented oxidative stress,18 both of which are believed to have 
pivotal roles in development of MeS itself and in its further 
  morbidities.19 It has been recently reported that even with the 
same body mass index (BMI), subjects with higher circulating 
inflammatory markers such as interleukin (IL)-6 are more 
likely to have insulin resistance.20 Low vitamin D status has 
been linked to inflammatory endothelial dysfunction in both 
diabetic and nondiabetic subjects.21,22 The oxidative-stress 
attenuating effect of vitamin D is a new finding that has been 
related to its anticancer effect.23 However, some other studies 
indicated that 1,25(OH)2D enhances inflammatory reaction in 
both human and murine adipocyte culture medium.24
In this study it was hypothesized that in the presence of 
high WC, vitamin D status is a contributing factor in MeS. To 
examine this hypothesis, a case-control study was conducted 
on nonmenopausal women residing in Tehran to: a) compare 
vitamin D status between subjects with and without MeS; 
b) determine the relationship between circulating 25(OH)D 
and the components of MeS; and c) examine the relationship 
between 25(OH)D and certain oxidative stress and inflam-
matory biomarkers.
Subjects and methods
Study design
This was a case-control study performed during the fall and 
winter, 2009–2010. Considering the higher prevalence of 
obesity and MeS in women than in men in Iran25 and the 
possible effects of menopause on the metabolism of bone 
and calcitropic hormones, only nonmenopausal women were 
studied in this research project. On the first visit, full informa-
tion on the study design and objectives were given to all sub-
jects in a face-to-face interview before they signed a written 
informed consent. A general questionnaire on demographic 
data and duration of direct sun exposure, based on recalled 
usual number of minutes/hours spent in daylight, was also 
completed. Duration of daily sun exposure was categorized 
as less than 10 minutes, 10 minutes to 1 hour, 1–2 hours and 
more than 2 hours.26 Then, blood pressure was measured 
and subjects were requested to return after an overnight 
(12–14 hours) fast for blood sampling. In this study, MeS 
was defined according to the National Cholesterol Education 
Program (NCEP)/Adult Treatment Panel (ATP) III criteria.1 
The scientific and ethical issues of this study were approved 
by the Research Council and the Ethical Committee of the 
National Nutrition and Food Technology Research Institute 
(NNFTRI), respectively.
Subjects
To find 100 women with MeS, 375 women with abdominal 
obesity from health centers and school staffs from Tehran 
were examined. The inclusion criteria were: 1) willingness 
to participate; 2) aged 30–50 years; 3) being nonmenopausal; 
4) waist circumference $88 cm; 5) absence of any clini-
cal disease; 6) not being pregnant or lactating; and 7) not 
receiving any nutritional supplement for at least 3 months 
preceding the study. This latter criterion was actually found 
necessary because irregular supplement use was common and 
impossible to quantify accurately. Women who met three out 
of five criteria of NCEP/ATP III (including high WC), were 
identified as having MeS and allocated to the cases group. 
Of the remaining subjects, 100 age- and residence region-
matched women were selected as a control group.
Anthropometry and blood pressure
Weight was measured with light clothes and without shoes 
to the nearest 0.1 kg using a digital scale (Seca 840; Seca 
GmbH, Hamburg, Germany). Height was measured without 
shoes to the nearest 0.1 cm with a measuring tape mounted 
onto the wall. A triangular ruler was put on the top of the 
subject’s head and then the number on the measuring tape 
at the intercept of the ruler and the tape was considered as 
the subject’s height. BMI was calculated using the equation 
BMI = weight (kg)/height(m)2. Hip circumference (HC) and 
WC were both measured by a measuring tape to the nearest 
0.1 cm. WC was determined at the midpoint between the Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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lowest rib and iliac crest while the subject was in a standing 
position and after expiration. Systolic blood pressure (SBP) 
and diastolic blood pressure (DBP) were measured in a seated 
position, after a 5-minute rest, using a digital sphygmoma-
nometer (BC08; Beurer GmbH, Ulm, Germany).
estimation of body fat mass (FM)
The percentage of body FM was evaluated using a bioelec-
trical impedance analysis (BIA) system (Quadscan 4000; 
BodyStat Ltd, Onchan, Isle of Man, UK).
Laboratory investigations
Blood sample handling
Venous blood samples collected after 12–14 hours fasting 
were transferred into two tubes, either with or without the 
anticoagulant sodium fluoride. Plasma recovered from 
the anticoagulated blood sample was used to measure 
  glucose and lipids within 2 hours of sample collection. Sera 
obtained after centrifugation of clotted samples at 1000 × g 
at room temperature were stored in aliquots at -80°C until 
the day of analysis.
Glycemic status and lipid profile
Plasma glucose, triglycerides (TG), total cholesterol, low-
density lipoprotein cholesterol (LDL-C), and high-density 
lipoprotein cholesterol (HDL-C) were measured using enzy-
matic colorimetric methods (all from Pars Azmoon, Tehran, 
Iran). Serum insulin was determined by immunoradiometric 
assay (IRMA) using a commercial kit (Biosource Diag-
nostics, Aartrijke, Belgium) and a gamma-counter system 
(Gamma I; Genesys, Grand Blanc, MI). Insulin resistance 
was evaluated by homeostasis model assessment of insulin 
resistance (HOMA-IR) index calculated using the following 
equation:27
  HOMA-IR =   fasting plasma glucose (mmol/L) × serum 
insulin (mU/L)/22.5
Inflammatory and oxidative stress biomarkers
Serum concentrations of hsCRP were measured by immu-
noturbidometric method (Pars Azmoon, Tehran, Iran) with 
the aid of an auto-analyzer (Selectra E; Vital Scientific, 
Spankeren, the Netherlands). Malondialdehyde (MDA) was 
measured based on thiobarbituric acid reacting substances 
(TBARS) method as described originally28 with some minor 
modifications.29 For measuring total antioxidant capacity 
(TAC), a colorimetric method with Azino-bis(3-methylb
enzothiazolin-6-sulfonic acid) diammonium salt (ABTS) 
reagent was used.30
circulating 25(Oh)D, intact parathyroid  
hormone (iPTh) and osteocalcin
Serum 25(OH)D was assayed using high-performance liquid 
chromatography (HPLC) as described earlier.31 In this study, 
vitamin D status was defined based on serum concentration 
of 25(OH)D as: deficiency #27.5 nmol/L; insufficiency 27.5 
#25(OH)D ,50 nmol/L; and sufficiency $50 nmol/L.32 
Serum iPTH concentrations were determined using enzyme-
linked immunosorbant assay (ELISA) kits (DRG Instruments 
GmbH, Marburg, Germany and Biosource Diagnostics, 
Aartrijke, Belgium, respectively) and a plate reader (Stat Fax 
3200; Awareness Technology Inc, Palm City, FL). The intra- 
and interassay variations for all ELISA tests were less than 
5% and 6%, respectively, as stated by the manufacturers.
Statistical analyses
Data were expressed as mean ± standard deviation (SD). 
For quantitative data, comparison between groups was made 
using Student’s t-test. To control confounding factors in 
comparing data between groups, analysis of covariance was 
employed. Qualitative data was compared between groups 
using the Chi square test. Correlations between two sets of 
data were evaluated using Pearson’s equation. To predict the 
relationship between circulating 25(OH)D and MeS compo-
nents, stepwise regression analysis was used. All statistical 
analyses were performed using Statistical Package for Social 
Sciences (SPSS) (v 16; SPSS Inc, Chicago, IL). In this study 
P , 0.05 was considered significant.
Results
Of the population examined for MeS, 28.3% met the NCEP/
ATP III criteria. Subjects with MeS had significantly higher 
BMI, WC and FM. However, there was no significant 
difference in circulating 25(OH)D3 or intact parathyroid 
  hormone (iPTH) between groups. Serum osteocalcin, a 
vitamin D-dependent bone protein, was significantly lower 
in women with MeS than in the control group (Table 1). 
The difference remained significant even after controlling 
for BMI (P , 0.001), WC (P = 0.001) and FM (P = 0.002). 
Neither duration of sun exposure (χ2 = 2.478, P = 0.479) nor 
vitamin D status (Table 2) differed significantly between 
the two groups. Duration of daily direct sun exposure in 
77.2% of the cases and 72.4% of the controls was between 
10–60 minutes, and in respectively 25% and 31.6% was 
less than 10 minutes. Serum hsCRP concentration was 
significantly higher in the MeS group, compared to the 
controls (P , 0.001). The difference remained significant 
even after controlling for BMI (P = 0.011), WC (0.014) Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Table  1  The  clinical  and  biochemical  characteristics  of  study 
population
Variables Groups P-value
Case  
mean (SD)
Control  
mean (SD)
Age (years) 42.0 (8.5) 42.3 (5.6) 0.79
Weight (kg) 82.4 (11.5) 76.0 (11.5) ,0.001
height (cm) 157.7 (6.2) 158.0 (6.0) 0.74
BMi (kg/m2) 33.1 (15.4) 30.4 (4.5) ,0.001
Wc (cm) 101.4 (8.2) 95.7 (9.8) ,0.001
hip circumference (cm) 108.1 (9.2) 104.5 (7.4) 0.003
Whr 0.93 (0.05) 0.91 (0.05) 0.01
FM (%) 41.6 (6.1) 39.7 (4.8) 0.02
SBP (mmhg) 122.5 (16.2) 112.6 (12.5) ,0.001
DBP (mmhg) 76.7 (11.3) 71.4 (9.7) ,0.001
glucose (mg/dL) 101.2 (13.5) 91.9 (10.0) ,0.001
Tg (mg/dL) 183.1 (74.2) 104.6 (43.3) ,0.001
cholesterol (mg/dL) 194.4 (40.2) 170.1 (33.5) ,0.001
LDL-c (mg/dL) 105.5 (24.3) 91.7 (21.5) ,0.001
hDL-c (mg/dL) 41.3 (9.1) 50.9 (9.9) ,0.001
insulin (μU/mL) 17.4 (8.9) 15.3 (7.5) 0.07
hOMA-ir 4.1 (2.0) 3.4 (1.7) 0.01
25(Oh)D (nmol/L) 16.7 (16.4) 13.9 (14.1) 0.21
MDA (nmol/L) 3.7 (0.8) 3.9 (1.1) 0.19
TAc (mmol/L of BSA  
equivalent)
1.4 (0.5) 1.3 (0.3) 0.06
hscrP (mg/L) 3.4 (3.3) 2.0 (1.9) ,0.001
iPTh (pg/mL) 47.3 (30.8) 50.2 (30.3) 0.572
Osteocalcin (ng/mL) 0.8 (1.5) 1.8 (2.6) 0.002
Abbreviations: BMi, body mass index; BSA, bovine serum albumin; DBP, diastolic 
blood  pressure;  FM,  fat  mass;  hDL-c,  high-density  lipoprotein  cholesterol; 
hOMA-ir,  homeostasis  model  assessment  of  insulin  resistance;  hscrP,  highly 
sensitive c-reactive protein; iPTh, intact parathyroid hormone; LDL-c, low-density 
lipoprotein cholesterol; MDA, malondialdehyde; SBP, systolic blood pressure; TAc, 
total antioxidant capacity; Tg, triglycerides; Wc, waist circumference; Whr, waist-
to-hip ratio; 25(Oh)D, 25-hydroxyvitamin D.
Table 2 The occurrence of vitamin D deficiency in women with 
and without metabolic syndrome
Vitamin D status MeS Control
Deficiency 86 (86) 89 (89)
Insufficiency 9 (9) 7 (7)
Sufficiency 5 (5) 4 (4)
Notes: χ2 = 0.850, P = 0.654.
and FM (P = 0.005). When comparison was made only in 
those subjects with insulin resistance (HOMA-IR . 2.4),33 
hsCRP was still higher in the MeS group (n = 79) than in 
the control group (n = 61) (P , 0.001). Serum 25(OH)D 
negatively correlated with hsCRP (r = -0.331, P = 0.002) and 
FM (r = -0.326, P = 0.004) in the whole study population. 
Association between 25(OH)D and hsCRP disappeared after 
controlling for FM (r = -0.212, P = 0.065).
 On evaluating the correlations separately in the two 
groups, 25(OH)D inversely correlated with hsCRP in women 
with and without MeS (r = -0.344, P = 0.016; and r = -0.357, 
P = 0.042, respectively). However, after controlling for BMI 
or FM, only in the MeS group did the correlation remain 
significant (r = -0.370, P = 0.012 and r = -0.305, P = 0.039, 
respectively). Serum MDA and TAC also did not differ 
significantly between the two groups. Only the MeS group, 
showed a significant correlation between 25(OH)D and TAC 
(r = -0.284, P = 0.048), which remained significant even after 
controlling for BMI (r = -0.335, P = 0.026), FM (r = -0.347, 
P = 0.021) and WC (r = -0.228, P = 0.031). The association, 
however, disappeared after controlling for plasma glucose 
(r = -0.162, P = 0.133).
When data were categorized according to vitamin D 
status, only the MeS subjects with vitamin D deficiency 
showed significantly higher plasma glucose concentrations as 
compared to those with vitamin D insufficiency or sufficiency 
(104.0 ± 11.7, 83.0 ± 11.3 and 83.2 ± 9.9 mg/dL, respec-
tively, P , 0.001). Interestingly, their WC (100.9 ± 9.7, 
102.3 ± 10.2 and 108.6 ± 12.2 cm, respectively, P = 0.240) 
or waist-to-hip ratio (WHR) (0.94 ± 0.06, 0.97 ± 0.03 and 
0.92 ± 0.02, respectively) did not differ significantly. In this 
group, none of the other MeS components had a significant 
difference among the categorized subgroups.
In stepwise regression analysis to establish a model to 
predict hsCRP with the components of MeS as independent 
variables, two models were obtained in which WC was the only 
predictor in both MeS and control groups, explaining 4.9% and 
6.7% of hsCRP variability, respectively (Table 3). However, 
when 25(OH)D was added to the independent variables, in the 
control group, two models were obtained. In model 1, again WC 
was the only predictor explaining 29.9% of hsCRP   variability. In 
model 2, both WC and 25(OH)D were the predictors explaining 
45.7% of the variability. In the MeS group there was only one 
model in which 25(OH)D was the main predictor of hsCRP 
explaining 8.4% of hsCRP variability (Table 4).
In another analysis performed to predict plasma glucose 
in both groups with 25(OH)D, osteocalcin, hsCRP, BMI, 
WC and FM as independent variables, none of the variables 
entered the model in the control group. In the MeS group, 
however, only 25(OH)D entered the model, explaining 30.6% 
of plasma glucose variability (P , 0.001) (Table 5).
Discussion
The occurrence rate of 28.3% of MeS in our subjects is note-
worthy as only women with WC above 88 cm, who were all 
overweight or obese, were examined for the criteria of MeS. 
Although women with MeS had higher BMI, WC and FM, 
this finding indicates that abdominal obesity as defined by Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Table 3 Stepwise multivariate linear regression analysis with hscrP as dependent variable in the whole study population
Group Independent variables B SE β t P-value
WC, FPG, HDL, TG, SBP and DBP
MeS
Model 1: WC 0.074 0.034 0.221 2.188 0.031
Control
Model 1: WC 0.064 0.025 0.259 2.581 0.011
WC, FPG, HDL, TG, SBP, DBP  
and 25(OH)D
MeS
Model 1: 25(OH)D -0.059 0.029 -0.289 -2.048 0.046
Control
Model 1: WC 0.130 0.036 0.547 3.640 0.001
Model 2: 25(OH)D -0.059 0.020 -0.400 -2.946 0.006
WC 0.142 0.032 0.601 4.426 ,0.001
Abbreviations: 25(Oh)D, 25-hydroxyvitamin D; DBP, diastolic blood pressure; FPg, fasting plasma glucose; hDL-c, high-density lipoprotein cholesterol; hscrP, highly 
sensitive c-reactive protein; LDL-c, low-density lipoprotein cholesterol; Tg, triglycerides; Wc, waist circumference.
Table 4 Stepwise multivariate linear regression analysis with hscrP as dependent variable
Group Independent variables B SE β t P-value
WC, HDL, FPG, SBP, DBP  
and 25(OH)D
MeS
Model 1: 25(OH)D -0.059 0.029 -0.289 -2.048 0.046
Control
Model 1: WC 0.130 0.036 0.547 3.640 0.001
Model 2: 25(OH)D -0.059 0.020 -0.400 -2.946 0.006
WC 0.142 0.032 0.601 4.426 ,0.001
Abbreviations: DBP, diastolic blood pressure; FPg, fasting plasma glucose; hDL-c, high-density lipoprotein cholesterol; hscrP, highly sensitive c-reactive protein; LDL-c, 
low-density lipoprotein cholesterol; Tg, triglycerides; Wc, waist circumference; 25(Oh)D, 25-hydroxyvitamin D.
NCEP/ATP III,1 despite its pivotal role, is not sufficient for 
development of MeS. Adipose tissue dysfunction may be more 
relevant to insulin resistance and other metabolic changes 
observed in MeS than the amount of fat mass itself.34 In sup-
port of this notion, it has been reported that in young South 
Asian men, insulin resistance could be present even in the 
absence of increased intraperitoneal fat and this might be due 
to the large size and dysfunction of subcutaneous abdominal 
adipocytes.35 More work is needed to elucidate the role of 
adipose tissue cellularity and function in MeS development.
High occurrence of vitamin D deficiency and insuffi-
ciency in both groups of women with and without MeS (86% 
and 89%, respectively) is quite noticeable. Poor vitamin D 
status in obesity has already been reported.36 It is believed 
that extra body fat, by sequestrating vitamin D, may reduce 
its bioavailability.7 The reasons for this high prevalence could 
be many: including blood sampling during the cold season; 
the high latitude of Tehran; air pollution; very inefficient 
direct sun exposure; and the fact that there is no vitamin D 
fortification program ongoing in Iran at this time. Moreover, 
according to the Islamic regulations, women must be veiled 
so that only face and hands (from wrist to the fingers) are 
allowed to be exposed. This may also contribute to the high 
occurrence of poor vitamin D status in our subjects.
The link between vitamin D status and metabolic syn-
drome has been, and still is, under debate.11,37 We found no 
difference in circulating 25(OH)D concentrations or vitamin 
D status between women with and without MeS. However, 
lower vitamin D status was accompanied by higher glucose 
concentrations and 25(OH)D was found to be the predictor 
of plasma glucose only in women with MeS. The relationship 
between vitamin D and glycemic status has been studied in 
both diabetic and nondiabetic subjects.38,39 In a recent clinical 
trial, vitamin D replenishment has led to the improvement of 
glycemic status in the subjects with T2D.40 Some evidence indi-
cates that 1,25(OH)2D, the active form of vitamin D, can boost 
insulin secretion by enhancing calcium flux in pancreatic beta 
cells.41 An in vitro study showed that 1,25(OH)2D can induce 
the expression of insulin receptor and insulin responsiveness 
in U-937 human promonocytic cells.42
In the current study, serum 25(OH)D was not associated 
with lipid profile, WC, WHR, and BMI. Unlike this finding, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Table  5  Stepwise  multivariate  linear  regression  analysis  with 
plasma glucose as dependent variable in women with MeS
Independent  
variables
B SE β t P-value
WC, BMI, FM,  
hsCRP, OST  
and 25(OH)D
Model 1: 25(OH)D -0.399 0.100 -0.553 -3.984 ,0.001
Abbreviations:  BMi,  body  mass  index;  FM,  fat  mass;  hscrP,  highly  sensitive 
c-reactive  protein;  OST,  osteocalcin;  Wc,  waist  circumference;  25(Oh)D, 
25-hydroxyvitamin.
the association of vitamin D status with some components 
of MeS such as serum HDL and triglycerides has been 
reported.43 Data from the Third National Health and Nutrition 
Examination Survey (NHANESIII) showed an inverse asso-
ciation between 25(OH)D and MeS.44 In a study performed 
on 1017 morbidly obese subjects (68% female), parathyroid 
hormone (PTH) was identified as the predictor of MeS, even 
though no relationship between serum 25(OH)D and MeS 
was observed.45
Circulating 25(OH)D has been inversely associated with 
MeS in 1654 American adults independent of calcium intake 
and PTH, which were positively associated with MeS in older 
men.46 Other studies, however, have failed to show any con-
tribution of vitamin D status in MeS.47–49 In a cross-sectional 
study on 542 Arab Americans, only men showed an associa-
tion between vitamin D deficiency and components of MeS50 
and there was no such association in Asian Indians at all.49 In 
the latter study, the prevalence of MeS in 441 Asian Indians, 
comprising 237 men and 204 women, was 27.9% and the 
occurrence of vitamin D insufficiency, defined as 25(OH)
D , 50 nmol/L, was 65.5% with no gender difference.49 The 
discrepancies seen in the results of studies may be due to 
the different study populations, the seasons of the studies and 
the methods used for determination of 25(OH)D. The very high 
occurrence of vitamin D deficiency in our subjects could be due 
to blood sampling during cold seasons, when dermal synthesis 
of vitamin D is negligible. Moreover, it has been demonstrated 
that both radioimmunoassay (RIA) and competitive protein-
binding assay (CPBA) may overestimate circulating 25(OH)D, 
compared to the HPLC method,31 that was used in this study.
The significantly lower serum concentrations of osteocal-
cin in women with MeS compared to the control group was 
of great importance. Lower serum osteocalcin concentra-
tions in MeS have also been reported in other studies.14,15,51,52 
Increased risk of MeS, independent of serum glucose, has 
been observed in Korean men and women who were in the 
lower quartiles (Q1–Q3) of serum osteocalcin, compared to 
those in the highest quartile.14
An MeS-related pro-inflammatory state seems to have a 
determining role in the further morbidities ascribed to MeS, 
including diabetes53 and cardiovascular disease (CVD).54
Assuming truncal fat being the core feature of MeS,2 the 
other components, notably inflammation, may emanate from 
the abdominal excess fat.55 However, significantly higher 
serum hsCRP in our subjects with MeS compared to the con-
trol group even after controlling for WC and FM indicates that 
systemic inflammation often accompanied by obesity may not 
originate solely from the adipose tissue. Lower inflammatory 
status, as judged by serum concentrations of CRP, has been 
suggested to have a protective role in the   so-called “metaboli-
cally healthy but obese” phenotype against such comorbidities 
as cardiovascular disease (CVD).56 It has been hypothesized 
that chronic inflammatory stimuli together with diminished 
anti-inflammatory mechanisms may have a role in metabolic 
derangements and endothelial dysfunction in MeS.57,58 Dietary 
pattern may also contribute to the inflammatory process. 
Higher intakes of fruits and vegetables, which are rich in 
anti-inflammatory antioxidants, were inversely associated 
with serum levels of CRP and development of MeS,59 while 
red meat,60 high fat dairy products61 and hydrogenated oil62 
consumption was associated with higher circulating inflam-
matory biomarkers and greater risk of MeS.
An inverse association between serum 25(OH)D and 
hsCRP may support the suggestion of an anti-inflammatory 
function of vitamin D. Though we found no significant dif-
ference in vitamin D status between women with and without 
MeS, 25(OH)D was the only predictor of both hsCRP and 
plasma glucose in the subjects with MeS.
Considering the anti-inflammatory effects of cholecalciferol,63 
poor vitamin D status may contribute to the systemic inflam-
mation often seen in obesity, thus favoring other metabolic 
derangements like insulin resistance and raised blood glucose. 
The possible anti-inflammatory effects of vitamin D must be 
evaluated in the controlled clinical trials.64
This study had some limitations. Blood samples were drawn 
during the cold seasons, when dermal synthesis of vitamin 
D is minimal, so the vitamin D status of our subjects did not 
necessarily reflect their status for the whole year. Because of the 
high proportion of vitamin D deficiency in both groups, it was 
difficult to show the differences, if any. Moreover, only women 
were enrolled in the study. Therefore the relationship between 
vitamin D status and MeS in men remains to be studied.
In conclusion, various degrees of vitamin D deficiency 
had more than 85% prevalence among overweight/obese 
middle-aged women in Tehran who participated in this 
study. Although there was no significant difference in either Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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serum 25(OH)D or vitamin D status between women with 
and without MeS, 25(OH)D was a predictor of hsCRP, the 
biomarker of systemic inflammation, in women with MeS 
but not in the controls. Thus, vitamin D status may, at least 
in part, be a determining factor of systemic inflammation and 
the related metabolic derangements of MeS.
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